Literature DB >> 22936391

Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer.

Katharina Heusinger1, Sebastian M Jud, Lothar Häberle, Carolin C Hack, Peter A Fasching, Martina Meier-Meitinger, Michael P Lux, Carsten Hagenbeck, Christian R Loehberg, Thomas Wittenberg, Claudia Rauh, Florian Wagner, Michael Uder, Arndt Hartmann, Rüdiger Schulz-Wendtland, Matthias W Beckmann, David L Wachter.   

Abstract

There is growing evidence that certain breast cancer (BC) risk factors specifically increase the risk for specific molecular tumor subtypes. Different molecular subtypes of BC can partly be described by analyzing proliferation in tumors. Very few data are available regarding the association of mammographic density (MD), as a BC risk factor, with proliferation. The aim of this study was to analyze the association between Ki-67 expression in BCs and MD. In this case-only study, data on BC risk factors, hormone receptor expression, and MD were available for 1,975 patients with incident BC. MD was assessed as percentage mammographic density (PMD) using a semiautomated method by two readers for every patient. The association of the Ki-67 proliferation index and PMD was studied using multifactorial analyses of covariance (ANCOVA), with PMD as the target variable and including well-known factors that are also associated with MD such as age, parity, use of hormone replacement therapy (HRT), and body mass index (BMI). There were no significant differences in PMD between women with BC who had low and high Ki-67 values (P = 0.31). However, there were relevant differences in women with low BMI (P = 0.07), and in women using postmenopausal HRT (P = 0.06) as well as in women with low PR values (P = 0.07). In these subgroups, the Ki-67 expression index increased with decreasing PMD. Likewise PMD is correlated with BMI, parity status, and menopausal status stronger in patients with low proliferating tumors, and with progesterone receptor expression in patients with high proliferating tumors. MD correlates inversely with Ki-67 proliferation in BC tumors only in some subgroups of BC patients, defined by commonly known BC risk factors that are usually associated with MD as well.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936391     DOI: 10.1007/s10549-012-2221-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

Review 1.  [New prognostic and predictive markers for breast cancer].

Authors:  D L Wachter
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

2.  Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.

Authors:  P A Fasching; S Y Brucker; T N Fehm; F Overkamp; W Janni; M Wallwiener; P Hadji; E Belleville; L Häberle; F-A Taran; D Lüftner; M P Lux; J Ettl; V Müller; H Tesch; D Wallwiener; A Schneeweiss
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-01       Impact factor: 2.915

3.  Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study.

Authors:  Jinzhong Sun; Chuang Chen; Wen Wei; Hongmei Zheng; Jingping Yuan; Y I Tu; Feng Yao; Lijun Wang; Xiaoli Yao; Juanjuan Li; Yan Li; Shengrong Sun
Journal:  Oncol Lett       Date:  2015-07-06       Impact factor: 2.967

4.  Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients.

Authors:  C C Hack; L Häberle; K Geisler; R Schulz-Wendtland; A Hartmann; P A Fasching; M Uder; D L Wachter; S M Jud; C R Loehberg; M P Lux; C Rauh; M W Beckmann; K Heusinger
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

5.  Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.

Authors:  P A Fasching; A B Ekici; D L Wachter; A Hein; C M Bayer; L Häberle; C R Loehberg; M Schneider; S M Jud; K Heusinger; M Rübner; C Rauh; M R Bani; M P Lux; R Schulz-Wendtland; A Hartmann; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

Review 6.  Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk.

Authors:  Michael S Shawky; Carmela Ricciardelli; Megan Lord; John Whitelock; Vito Ferro; Kara Britt; Erik W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-12       Impact factor: 2.673

7.  Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data.

Authors:  Linda Abrahamsson; Kamila Czene; Per Hall; Keith Humphreys
Journal:  Breast Cancer Res       Date:  2015-08-21       Impact factor: 6.466

8.  High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium.

Authors:  Cecilia W Huo; Grace Chew; Prue Hill; Dexing Huang; Wendy Ingman; Leigh Hodson; Kristy A Brown; Astrid Magenau; Amr H Allam; Ewan McGhee; Paul Timpson; Michael A Henderson; Erik W Thompson; Kara Britt
Journal:  Breast Cancer Res       Date:  2015-06-04       Impact factor: 6.466

9.  Association between mammographic density and basal-like and luminal A breast cancer subtypes.

Authors:  Hilda Razzaghi; Melissa A Troester; Gretchen L Gierach; Andrew F Olshan; Bonnie C Yankaskas; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

10.  Possible influence of mammographic density on local and locoregional recurrence of breast cancer.

Authors:  Louise Eriksson; Kamila Czene; Lena Rosenberg; Keith Humphreys; Per Hall
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.